Akorn Poised For Ch. 11 Sale Following Failed $4.3B Merger

Law360 (February 12, 2020, 10:12 PM EST) -- Akorn Inc. said Wednesday it plans to sell all of its assets, potentially seeking Chapter 11 protection, to address litigation costs that have mounted in the wake of the generic-drug maker's failed $4.3 billion merger with Fresenius Kabi AG in 2018.

Fresenius walked away from its proposed acquisition of Akorn in April of that year after regulatory compliance issues at Akorn came to light. Akorn's stock then plummeted from $19.70 per share to $13.05 within the span of a day, and the company has since faced a slew of suits brought by investors.

Wednesday's announcement comes less than a week after...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!